It's important to check with your health care provider to determine if participating in a clinical trial is right for you. Learn more about clinical trials, what questions to ask before participating and the drug approval process.
Clinical trials play an important role in the development of new and better treatments for psoriasis and psoriatic arthritis. Through clinical trials, companies can learn what treatments are safe and effective for psoriatic diseases, and possibly bring those drugs to the marketplace.
The purpose of this study is to determine the relationship between two types of cell signals (type I IFN and TNF) in psoriatic skin prior to and during treatment with etanercept and correlate that information with the degree of the improvement in the psoriasis.
Condition: Psoriasis | Phase: Phase 4 | Minimum Age: 18 Years
This study is being conducted to evaluate the safety, tolerability, and efficacy of KD025 in adult subjects with moderate to severe chronic plaque psoriasis.
Condition: Psoriasis | Phase: Phase 2 | Minimum Age: 18 Years
This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
Condition: Chronic Plaque Psoriasis | Phase: Phase 2 | Minimum Age: 18 Years
Biologics are used to treat conditions such as moderate-to-severe psoriasis, a chronic condition that impairs quality of life as much or more than other major medical conditions. Biopharmaceuticals are medications which are are isolated from biological sources including microorganisms, animals or humans. These medications generally function to decrease inflammation or disrupt the inflammatory cycle. Patients are often apprehensive about choosing a biologic medication over other options due to anxiety regarding the need for regular injections, leaving the patient undertreated and continuing to suffer with psoriasis. Reducing fears of injections may improve adherence to treatment and may improve treatment outcomes. Fear of injection is inherently subjective and may be easily modified. Anchoring is the tendency for humans to rely on a specific value when making decisions and to make judgments relative to that value. Patients who have never taken an injection will subjectively view the idea of taking an injection relative to the "not taking any injection" baseline. This comparison is scary and represents a considerable hurdle to taking a new injectable medication that may be otherwise optimal for their treatment. Resetting the anchor may be all that is needed to help patients overcome fear of injection. The objective is to assess whether patients offered a once monthly injectable biologic would be more likely to accept that biologic medication if they are first counseled about a daily injection.
Condition: Moderate-to-severe Psoriasis | Phase: N/A | Minimum Age: 18 Years
This study evaluates the potential of HPA suppression in adolescent patients with moderate to severe plaque psoriasis when using DFD01 Spray (twice daily for either 15 or 29 days) vs. Comp01 Lotion (twice daily for 15 days).
Condition: Plaque Psoriasis | Phase: Phase 3 | Minimum Age: 12 Years